Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017

Date: November 21, 2017
Pages: 163
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A075F648F69EN
Leaflet:

Download PDF Leaflet

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 5, 5, 9, 1, 13, 7 and 3 respectively.

Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ankylosing Spondylitis (Bekhterev's Disease) - Overview
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
AbbVie Inc
Adello Biologics LLC
Allergan Plc
Alteogen Inc
Amgen Inc
Biocad
Biocon Ltd
Bionovis SA
Celgene Corp
Coherus BioSciences Inc
Fresenius SE & Co KGaA
Galapagos NV
Genor BioPharma Co Ltd
Immunwork Inc
Innovent Biologics Inc
Mycenax Biotech Inc
Nichi-Iko Pharmaceutical Co Ltd
Novartis AG
Oncobiologics Inc
Protalix BioTherapeutics Inc
Reliance Life Sciences Pvt Ltd
Sandoz International GmbH
Shanghai Pharmaceutical Co Ltd
Sun Pharma Advanced Research Company Ltd
UCB SA
Xbrane Biopharma AB
Ankylosing Spondylitis (Bekhterev's Disease) - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCD-085 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimekizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNX-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNX-514 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEISCO-III-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
risankizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
secukinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-2122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-2158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
thalidomide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tildrakizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
upadacitinib tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTP-43742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones
Featured News & Press Releases
Nov 06, 2017: Novartis seeks leadership with Cosentyx showing no radiographic progression in ankylosing spondylitis at 4 years
Oct 30, 2017: Novartis to present first of its kind evidence for Cosentyx on potential to maintain mobility in patients with AS and PsA
Jun 15, 2017: Novartis Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib
Nov 14, 2016: Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
Oct 31, 2016: Novartis Wins Prestigious Prix Galien Foundation Award, Cosentyx as Best Biotechnology Product
Sep 28, 2016: NICE Issues Positive Final Appraisal Determination For Cosentyx (Secukinumab)
Sep 12, 2016: Innovent IBI303 to Initiate Pivotal Clinical Comparability studies with Adalimumab
Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis
Aug 04, 2016: NICE Issues Positive Final Appraisal Determination For Cosentyx
Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada
Jan 20, 2016: Diplomat Announces COSENTYX Availability for the Treatment of Two New Indications
Jan 15, 2016: Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
Dec 23, 2015: Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Adello Biologics LLC, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Allergan Plc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alteogen Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocad, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Ltd, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bionovis SA, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corp, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Coherus BioSciences Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Fresenius SE & Co KGaA, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Galapagos NV, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co Ltd, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Immunwork Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics Inc, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by UCB SA, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Xbrane Biopharma AB, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Adello Biologics LLC
Allergan Plc
Alteogen Inc
Amgen Inc
Biocad
Biocon Ltd
Bionovis SA
Celgene Corp
Coherus BioSciences Inc
Fresenius SE & Co KGaA
Galapagos NV
Genor BioPharma Co Ltd
Immunwork Inc
Innovent Biologics Inc
Mycenax Biotech Inc
Nichi-Iko Pharmaceutical Co Ltd
Novartis AG
Oncobiologics Inc
Protalix BioTherapeutics Inc
Reliance Life Sciences Pvt Ltd
Sandoz International GmbH
Shanghai Pharmaceutical Co Ltd
Sun Pharma Advanced Research Company Ltd
UCB SA
Xbrane Biopharma AB
Skip to top


Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 60 pages
Charcot-Marie-Tooth Disease - Pipeline Review, H1 2016 US$ 2,000.00 Feb, 2016 · 56 pages
Raynauds Disease - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 49 pages

Ask Your Question

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: